Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

MMX mesalamine.

Danial E Baker1

  • 1College of Pharmacy, Washington State University, Spokane, Washington, USA.

Reviews in Gastroenterological Disorders
|September 8, 2006
PubMed
Summary
This summary is machine-generated.

New Multi-Matrix System (MMX) mesalamine tablets offer a once-daily oral treatment option. This formulation effectively delivers mesalamine to the colon, improving ulcerative colitis management.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Prospective Audit and Feedback of Targeted Antimicrobials Use at a Tertiary Care Hospital in the United Arab Emirates.

Antibiotics (Basel, Switzerland)·2025
Same author

Sulopenem Etzadroxil/Probenecid.

Hospital pharmacy·2025
Same author

Axatilimab.

Hospital pharmacy·2025
Same author

Respiratory Syncytial Virus Vaccine (mRNA).

Hospital pharmacy·2024
Same author

Resmetirom.

Hospital pharmacy·2024
Same author

Cefepime/Enmetazobactam.

Hospital pharmacy·2024
Same journal

Prevalence and risk factors of fecal incontinence in community-dwelling men.

Reviews in gastroenterological disorders·2010
Same journal

Diarrhea - novel transdermal patch vaccine to prevent travelers' diarrhea.

Reviews in gastroenterological disorders·2010
Same journal

Peptic ulcer bleeding following therapeutic endoscopy: a new indication for intravenous esomeprazole.

Reviews in gastroenterological disorders·2010
Same journal

Diarrhea--cryptosporidial diarrhea in patients with AIDS: impressive results with Rifaximin.

Reviews in gastroenterological disorders·2009
Same journal

Methylnaltrexone bromide: new drug for the treatment of opioid-induced bowel dysfunction.

Reviews in gastroenterological disorders·2009
Same journal

Antimicrobial resistance and eradication strategies for Helicobacter pylori.

Reviews in gastroenterological disorders·2009
See all related articles

Area of Science:

  • Gastroenterology
  • Pharmaceutics
  • Drug Delivery Systems

Background:

  • Current ulcerative colitis and Crohn's disease treatments often exhibit suboptimal drug release locations.
  • The pharmaceutical industry is actively developing advanced drug delivery systems for inflammatory bowel disease (IBD).

Purpose of the Study:

  • To evaluate the efficacy of a novel Multi-Matrix System (MMX) mesalamine formulation for treating ulcerative colitis.
  • To compare the delivery profile of MMX mesalamine with existing oral mesalamine formulations.

Main Methods:

  • Development of a novel oral mesalamine formulation utilizing a Multi-Matrix System (MMX) technology.
  • The MMX system is designed for targeted drug release in the ileum and colon.

Main Results:

Related Experiment Videos

  • The MMX mesalamine tablet is formulated for once-daily administration.
  • The MMX coating initiates dissolution in the ileum, targeting drug delivery to the colon.
  • This targeted delivery may offer advantages over proximal-release formulations.

Conclusions:

  • MMX mesalamine presents a potentially improved therapeutic option for ulcerative colitis.
  • The once-daily oral MMX formulation offers enhanced convenience and targeted delivery for ulcerative colitis treatment.